Sanofi wins appeal in spat with NICE over Sarclisa
1 hour ago · Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...
Press Room - Sanofi US News
Sep 20, 2024 · Advancing SARCLISA in multiple myeloma. Sanofi continues to advance SARCLISA as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six …
Press Room - Sanofi US News
Aug 8, 2024 · GMMG-HD7 is one of six phase 3 studies to report positive results for Sarclisa in multiple myeloma (MM), which includes four positive readouts of a Sarclisa-based quadruplet in the frontline setting. Results reinforce the potential of Sarclisa as a backbone therapy when added to the current standard-of-care in various MM patient populations.
Press Room - Sanofi US News
May 27, 2024 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activities.
Sanofi wins US approval for multiple myeloma drug in newly …
Sep 20, 2024 · The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed...
Sanofi wins appeal against negative Final Draft Guidance for its ...
2 hours ago · As part of this extended evaluation process, Sanofi are calling for increased flexibility so that eligible new patients do not lose an important combination treatment for their relapsed and refractory multiple myeloma (RRMM) in the future; Sanofi is committed to engaging further with NICE, NHS England, healthcare professionals, patients groups ...
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Sep 23, 2024 · Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in...
ASCO24: Sanofi’s Sarclisa looks to gain an edge in multiple myeloma
Jun 4, 2024 · Sarclisa is a CD38-directed cytolytic human monoclonal antibody that received its first FDA approval for the treatment of adults with previously multiple myeloma. Credits: nitpicker / Shutterstock. Soon after Sanofi announced that the US Food and Drug Administration (FDA) accepted its supplemental biologics licence application (sBLA) for ...
Isatuximab Quadruplet Approval Could Change MM Landscape
Oct 4, 2024 · RIO DE JANEIRO — Adding isatuximab, or Isa (Sarclisa, Sanofi-Aventis), to bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of patients with newly diagnosed,...
Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma …
Aug 8, 2024 · Sanofi’s Sarclisa (isatuximab) plus standard of care has been shown to extend the time that some multiple myeloma patients remain stable without disease progression. This was demonstrated in a Phase III trial (NCT03617731) with 662 newly diagnosed patients who were eligible for a stem cell transplant.
- Some results have been removed